Novartis

News

Lilly's breast cancer drug Verzenio approved in EU

Eli Lilly’s Verzenio breast cancer drug has been approved in Europe, as the pharma prepares to compete with established rivals from Pfizer and Novartis.

News

Roche aims to extend shelf life of Xolair with new prefilled...

The FDA has approved a new prefilled syringe formulation for Roche’s asthma drug Xolair, as the Swiss company aims to prolong its shelf life.

News

Lilly pushes into migraine market as Emgality approved in US

The FDA has approved Eli Lilly’s Emgality (galcanezumab) for migraine prevention in adults, the third in a group of new class of drugs for the condition.

News

Novartis, Bayer consider appeal as court says Avastin can be...

England’s High Court has ruled it is lawful to use Roche’s Avastin (bevacizumab) in an unlicensed use in wet age-related macular degeneration (AMD) instead of more expensive approved drugs

News

Spark/Novartis eye gene therapy nears EU market – but at wha...

Spark Therapeutics’ and Novartis Luxturna gene therapy for a rare inherited eye disease has been okayed by European regulators, paving the way for an EU licence in the coming months.

News

NICE rejects Novartis' CAR-T in adult lymphoma

NICE has said Novartis’ CAR-T therapy Kymriah cannot be funded by the NHS in adults with an aggressive form of lymphoma, calling for further discussions to get the drug on to the market.

Lilly's breast cancer drug Verzenio approved in EU

Roche aims to extend shelf life of Xolair with new prefilled...

Lilly pushes into migraine market as Emgality approved in US

Novartis, Bayer consider appeal as court says Avastin can be...

Spark/Novartis eye gene therapy nears EU market – but at wha...

NICE rejects Novartis' CAR-T in adult lymphoma

GBL joins CVC in €10.7bn takeover bid for Recordati

Discover a new era of healthcare panel engagement: Grounded ...

Novartis

Editor's Picks